



11/1/00 J (4)

RECEIVED PATENT OCT 25 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this RESPONSE TO NOTICE TO COMPLY and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage and post paid. Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Tami Barnas
Tami Barnas

10/2/00
Date of Deposit OCT 26 2000

Applicant: Linda A. Sherman)
Serial No.: 09/277,074) Group Art Unit: 1642
Filed: March 26, 1999) Examiner: M. Davis
Title: IN VIVO ACTIVATION OF TUMOR-)
SPECIFIC CYTOTOXIC T CELLS) Our Ref.: TSRI 443.1D4

TECH CENTER 1600/2900

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES (37 CFR §1.821-1.825)

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR §1.821-1.825 mailed June 13, 2000, enclosed is a Substitute Sequence Listing on paper copy, made in accordance with 37 CFR §1.821 - §1.825. Also enclosed is the Substitute Sequence Listing in computer readable form, submitted as required by 37 CFR §1.821(e), on which the Substitute Sequence Listing is labeled SCR2153S.APP.

Entry of the following amendments and consideration of the Remarks that follow is respectfully requested.

Please amend the above-identified application as follows: